Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Share-based Compensation: 2016-2025

Historic Share-based Compensation for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $17.7 million.

  • Tg Therapeutics' Share-based Compensation rose 49.88% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.0 million, marking a year-over-year increase of 52.49%. This contributed to the annual value of $42.5 million for FY2024, which is 12.15% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Share-based Compensation is $17.7 million, which was up 7.84% from $16.4 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Share-based Compensation ranged from a high of $36.5 million in Q4 2022 and a low of -$1.0 million during Q2 2022.
  • Its 3-year average for Share-based Compensation is $11.8 million, with a median of $11.8 million in 2024.
  • Per our database at Business Quant, Tg Therapeutics' Share-based Compensation plummeted by 106.13% in 2022 and then soared by 1,350.00% in 2023.
  • Quarterly analysis of 5 years shows Tg Therapeutics' Share-based Compensation stood at $14.4 million in 2021, then soared by 153.98% to $36.5 million in 2022, then tumbled by 74.31% to $9.4 million in 2023, then increased by 27.31% to $11.9 million in 2024, then skyrocketed by 49.88% to $17.7 million in 2025.
  • Its Share-based Compensation was $17.7 million in Q3 2025, compared to $16.4 million in Q2 2025 and $15.0 million in Q1 2025.